Results 161 to 170 of about 29,580 (292)

Predictors of Symptom Scores in Myeloproliferative Neoplasms: A Real‐World Retrospective Cohort Study

Cancer Medicine, Volume 14, Issue 23, December 2025.
ABSTRACT Background Symptom management in myeloproliferative neoplasms (MPN) remains challenging despite advancements in disease‐directed therapies. This study assessed the impact of demographic, clinical, laboratory and treatment‐related variables on total symptom scores (TSS) and individual symptom scores in patients with polycythemia vera (PV ...
Muhammad Ali Khan, Syed Arsalan Ahmed Naqvi, John K. Camoriano, Cecilia Y. Arana Yi, Jennifer T. Andres, Joshua L. Blocher, Heidi E. Kosiorek, Irbaz Bin Riaz, Jeanne M. Palmer   +8 more
wiley   +1 more source

CSF3R Mutations Imply Adverse Prognostic Impact in Adult Acute Myeloid Leukemia Patients: A Single‐Center Retrospective Study

Cancer Medicine, Volume 14, Issue 24, December 2025.
This study aimed to elucidate the clinical and prognostic relevance of CSF3R mutations in acute myeloid leukemia (AML), with a particular focus on their molecular characteristics, treatment responses, and survival outcomes. CSF3R mutations define a distinct high‐risk subset of AML, characterized by reduced remission rates, lower measurable residual ...
Jinjun Yang, Lian Wang, Min Zhu, Xinrong Xiang, Yu Wu, Ting Niu, Yuping Gong, Xinchuan Chen, Chuan He, Yang Dai, Xiao Shuai, Hongbing Ma   +11 more
wiley   +1 more source

Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS

, 2016
Mehrad Tavallai, Laurence Booth, Jane L. Roberts, William P. McGuire, Andrew Poklepovic, Paul Dent   +5 more
openalex   +2 more sources

Repurposing Acebutolol for Osteoporosis Treatment: Insights From Multi‐Omics and Multi‐Modal Data Analysis

Clinical Pharmacology &Therapeutics, Volume 118, Issue 6, Page 1463-1476, December 2025.
Overview of a multi‐omics based drug repurposing strategy. The systematic drug repurposing strategy included the following steps: (1) osteoporosis driver signaling networks were identified from multi‐omics data; (2) drug functional modules were obtained using a network fusion approach to integrate drug similarity information; (3) all drugs were ranked ...
Dan‐Yang Liu, Hui Shen, Jonathan Greenbaum, Qiao‐Rong Yi, Shuang Liang, Yue Zhang, Jia‐Chen Liu, Chuan Qiu, Lan‐Juan Zhao, Qing Tian, Kuan‐Jui Su, Zhe Luo, Li Wu, Xiang‐He Meng, Hong‐Mei Xiao, Yun Deng, Yang Li, Dragana Lovre, Vivian Fonseca, Fernando L. Sanchez, Li‐Jun Tan, Hong‐Wen Deng   +21 more
wiley   +1 more source

Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations [PDF]

, 2016
Barbui, T, Barosi, G, Birgegård, G, Cervantes, F, Griesshammer, M, Harrison, C., Hehlmann, R, Kiladjian, J-J, Kröger, N, Marchetti, M, McMullin, M F, Passamonti, F, Vannucchi, A   +12 more
core   +1 more source

Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era

, 2020
Lucia Masárová, Prithviraj Bose, Naveen Pemmaraju, Naval Daver, Lingsha Zhou, Sherry Pierce, Koji Sasaki, Hagop M. Kantarjian, Zeev Estrov, Srđan Verstovšek   +9 more
openalex   +2 more sources

Supplementary Methods from Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis

, 2023
Joe‐Elie Salem, Marie Bretagne, Baptiste Abbar, Sarah Léonard-Louis, Stéphane Éderhy, Alban Redheuil, Samia Boussouar, Lee S. Nguyen, Adrien Procureur, Frederic Stein, Charlotte Fenioux, Perrine Devos, Paul Gougis, Martin Dres, Alexandre Demoule, Dimitri Psimaras, Timothée Lenglet, Thierry Maisonobe, Marc Pineton de Chambrun, Guillaume Hékimian, Christian Straus, Jésus González-Bermejo, David Klatzmann, A. Rigolet, Perrine Guillaume-Jugnot, Nicolas Champtiaux, Olivier Benvéniste, Nicolas Weiss, Samir Saheb, Philippe Rouvier, Isabelle Plu, Estelle Gandjbakhch, Mathieu Kerneïs, Nadjib Hammoudi, Noël Zahr, Claudia Llontop, Capucine Morélot‐Panzini, Lorenz Lehmann, Juan Qin, Javid J. Moslehi, Michèlle Rosenzwajg, Thomas Similowski, Yves Allenbach   +42 more
openalex   +1 more source

Ruxolitinib withdrawal due to the COVID-19 [PDF]

, 2021
Marko Lucijanić, Rajko Kušec
openalex   +1 more source

Atypical chronic myeloid leukemia: From diagnosis to molecular features and therapeutic options

HemaSphere, Volume 9, Issue 12, December 2025.
ABSTRACT Atypical chronic myeloid leukemia (aCML) is a rare form of myelodysplastic (MDS)/myeloproliferative neoplasm (MPN) overlap disorder characterized by neutrophilic leukocytosis with circulating immature myeloid cells (IMC), frequent hepatosplenomegaly, and poor prognosis with high rates of leukemic transformation.
Alessandra Iurlo, Daniele Cattaneo, Umberto Gianelli, Francesco Passamonti   +3 more
wiley   +1 more source

Pulmonary arterial hypertension exacerbated by ruxolitinib [PDF]

, 2015
Harrison, C, Howard, L, Low, AT, Tulloh, RMR   +3 more
core   +2 more sources